Compare Google Inc (GOOG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Viatris Inc — how do they compare? Google Inc trades at $348.17 (market cap $4.24T), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Google Inc is far larger — about 211.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Viatris Inc for 57 Days on average.
| GOOG | VTRS | |
|---|---|---|
Market Cap | $4.24T | $20.03B |
Volume | 13,937,902 | 14,109,977 |
Sector | Media | Health |
52-Week High | $399.06 | $18.27 |
52-Week Low | $237.49 | $9.74 |
Typical Hold Time | 137 Days | 57 Days |
Enterprise Value | $4.13T | $32.15B |
Dividend Yield | 0.26% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $347.86, up 0.14% with strong technical momentum above key support levels. The stock shows robust fundamentals with revenue growth accelerating to $402.84B in 2025 and net income margins expanding to 32.8%. Recent earnings beats and a bullish analyst consensus at 87% buy ratings support the positive outlook, though elevated capital expenditures and regulatory scrutiny present near-term headwinds.
Alphabet's outlook remains favorable with AI-driven cloud growth and consistent earnings outperformance. The stock trades at a reasonable 17.3 P/E with 34% upside to the $435.24 consensus target. Key risks include massive AI infrastructure spending impacting cash flow and ongoing regulatory litigation. The technical setup suggests continued momentum toward resistance at $352-$354.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
